$262.96 12.75 (5.10%)
19:50 EDT DXCM Stock Quote Delayed 20 Minutes
Previous Close $262.96
Market Cap 23.16B
PE Ratio -710.70
Volume (Avg. Vol.) 1.51M
Day's Range 240.61 - 270.00
52-Week Range 107.44 - 306.71
Dividend & Yield N/A (N/A)
DXCM Stock Predictions, Articles, and Dexcom News
- From InvestorPlace
- From the Web
These ten growth stocks saw the highest percentage growth over the last decade, and some remain unknown to investors despite huge increases.
The fear-mongering media had quite a few factors to scare investors with last Friday: the U.S.-China trade war, President Trump’s latest tweets, and the plummeting S&P 500. Underneath the big selloff, would you ever guess that plenty of stocks made new 52-week highs that very same day?
Put these fast-growing stocks on your radar, if not in your portfolio, as your best shot at overcoming the market's summertime blues.
The stock charts of UNH, TWTR and PM are poised to start the new trading week on the verge of big moves. Here are the levels to keep an eye on.
These Internet of Things stocks should be on your stocks to buy list as they have slipped under the radar and continue to present unique long-term opportunities in the IoT space.
October has been volatile, but some stocks offer safety from the storm. Whether you’re just starting out or an investing veteran, these are core stocks to buy.
DexCom (DXCM) stock was on the rise Thursday following the release of a strong earnings report for the second quarter of 2018.
The trend of connected devices should provide plenty of opportunities for investors. The sector has nearly endless applications. So here are five companies to consider.
MedTech Stocks are hot, hot, hot. Here are five of the best to buy today for long-term growth.
Another dip in quarterly sales and profits confirms the worst fears for Fitbit stock holders as Fitbit Inc just can't find its lane.
Fitbit (FIT) is reportedly working on a version of Fibit for kids, but the device is still in the early stages of development.
The Fitbit investment in Sanos, a startup developing a coin-sized blood glucose monitor for diabetics, is proof that Fitbit has no intention of letting Apple dominate the health tracking market the same way it took over the smart watch market.
Fitbit stock hit an eight-month high before a recent pullback. But the "this time is different" story behind FIT stock isn't strong enough.
Fitbit stock got another boost on news it inked a deal with Dexcom to bring CGM data for diabetics to the Fitbit Ionic smartwatch.
With big dreams, it’s feast or famine for some of these money-losing companies, yet they remain attractive stocks to buy.
The overall ratings of 7 Health Care Equipment & Supplies stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, the ratings of 7 Health Care Equipment & Supplies stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The overall ratings of 9 Health Care Equipment & Supplies stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
From Analyst Ratings
Morgan Stanley analyst David Lewis maintained a Hold rating on Dexcom (DXCM – Research Report) today and set a price target of $278.00. The company’s shares closed last Monday at $262.63. According to TipRanks.com, Lewis is a 4-star analyst with an average return of 3.0% and a 53.9% success rate. Lewis covers the Healthcare sector,
From Simply Wall St
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/does-dexcom-inc-nasdaqdxcm-create-value-for-shareholders/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader